Cannabis Science Inc. Signs Agreement With MEDIWIET to Conduct Clinical Observational Study in the Netherlands - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Cannabis Science Inc. Signs Agreement With MEDIWIET to Conduct Clinical Observational Study in the Netherlands


Cannabis Science Inc. Signs Agreement With MEDIWIET to Conduct Clinical Observational Study in the Netherlands

PR Newswire

COLORADO SPRINGS, Colo., April 30, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in the development of cannabis based medicines is proud to announce a joint observational study with the MEDIWIET Patient Organization. 

MEDIWIET is a rapidly growing Dutch organization of patients using medicinal cannabis based medication.

The main purpose of the observational study is to further advance the knowledge of cannabis plant based product applications in various human disease conditions.   The study will be conducted with the approval from the Dutch regulators and it is anticipated that data collected will be published in a peer reviewed scientific journal.

"We are excited to initiate work on the observational clinical study with patients who use medicinal cannabis.  The long-term effects of using medicinal cannabis continue to be a subject of an ongoing debate. It is very important that we provide further scientific evidence for the benefit of patients and medical professionals alike," stated Mr. Mario Lap, President of European Operations and Director of Cannabis Science B.V.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com 
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824

SOURCE Cannabis Science, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here